{"version":3,"sources":["webpack:///./src/pages/Studies/IdentifyCalculatorValidation/Overview.js","webpack:///./src/images/identify.jpeg"],"names":["IdentifyOverviewPage","className","class","id","src","IdentifyLogo","href","module","exports"],"mappings":"4FAAA,qGAsQeA,UA9Pa,kBAC5B,8BACG,kBAAC,IAAD,MAEA,kBAAC,IAAD,MACC,6BAASC,UAAU,WACjB,yBAAKC,MAAM,aACV,wBAAID,UAAU,yBAAyBE,GAAG,SAA1C,qBACE,8BAGL,yBAAKD,MAAM,+BACX,4BAAQD,UAAU,kCAChB,yBAAKE,GAAG,aAAaC,IAAKC,OAE5B,0BAAMH,MAAM,SAAZ,wJACA,6BACA,0BAAMA,MAAM,SAAZ,yDAKF,6BAASD,UAAU,WAChB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,gDACtC,6BACF,wBAAIA,UAAU,6BAAd,gRAMF,wBAAIA,UAAU,6BAAd,oEAEA,uBAAGK,KAAO,wDAAV,UAFA,oFAQA,6BAASL,UAAU,WAClB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,kDACtC,6BACF,wBAAIA,UAAU,6BAAd,0FAMJ,6BAASA,UAAU,WAClB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,+CACtC,6BACA,wBAAIA,UAAU,6BACd,qDAEA,wBAAIA,UAAU,6BACd,uCADA,2IAIA,wBAAIA,UAAU,6BACb,oDAED,wBAAIA,UAAU,6BACd,uCADA,0OAKA,wBAAIA,UAAU,6BACd,uCADA,2FAOF,6BAASA,UAAU,WAChB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,gDACtC,6BACF,wBAAIA,UAAU,6BAChB,kDAEA,wBAAIA,UAAU,6BACd,uCADA,wDAGA,wBAAIA,UAAU,6BACd,oDAEA,wBAAIA,UAAU,6BACd,uCADA,6FAOH,6BAASA,UAAU,WAChB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,8CACtC,6BACF,wBAAIA,UAAU,6BAChB,iDAEA,wBAAIA,UAAU,6BACd,uCADA,2GAIA,wBAAIA,UAAU,6BACd,uCADA,0CAGA,wBAAIA,UAAU,6BACd,mDAEA,wBAAIA,UAAU,6BACd,uCADA,2FAIA,wBAAIA,UAAU,6BACd,uCADA,8IAOF,6BAASA,UAAU,WAChB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,6CACtC,6BACF,wBAAIA,UAAU,6BAAd,4PAKF,wBAAIA,UAAU,6BAAd,4nCAgBA,wBAAIA,UAAU,6BAAd,wIAIA,wBAAIA,UAAU,6BACd,qDAEA,wBAAIA,UAAU,6BACd,uCADA,uCAGA,wBAAIA,UAAU,6BACd,uCADA,iCAGA,wBAAIA,UAAU,6BACd,uCADA,wCAGA,wBAAIA,UAAU,6BACd,gDAEA,wBAAIA,UAAU,6BAAd,0KAOA,6BAASA,UAAU,WAClB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,iDACtC,6BACF,wBAAIA,UAAU,6BAAd,4NAKA,wBAAIA,UAAU,6BAAd,uIAOC,6BAASA,UAAU,WAChB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,+CACtC,6BACJ,wBAAIA,UAAU,6BACd,sCADA,2CAGA,wBAAIA,UAAU,6BACd,sCADA,0CAGA,wBAAIA,UAAU,6BACd,sCADA,uCAGA,wBAAIA,UAAU,6BACd,sCADA,sCAMA,6BAASA,UAAU,WAClB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,8EACtC,6BACF,wBAAIA,UAAU,6BACd,uCADA,qIAIA,wBAAIA,UAAU,6BAAd,+fASA,wBAAIA,UAAU,6BAAd,gWAUP,6BAASA,UAAU,WAClB,yBAAKC,MAAM,aACV,wBAAID,UAAU,0BAAd,IAAwC,kEACtC,6BACF,wBAAIA,UAAU,6BAAd,uZASL,kBAAC,IAAD,S,qBClQFM,EAAOC,QAAU,IAA0B","file":"component---src-pages-studies-identify-calculator-validation-overview-js-b82a2a0fc6eb7feabbf2.js","sourcesContent":["import React from 'react';\nimport '../../../components/style.scss';\nimport Helmet from '../../../components/helmet';\nimport Navbar from '../../../components/navbar';\nimport Footer from '../../../components/footer';\n\nimport IdentifyLogo from '../../../images/identify.jpeg'\n\nconst IdentifyOverviewPage= () => (\n<html>\n\t\t\t<Helmet>\n\t\t </Helmet>\n\t\t <Navbar />\n    <section className=\"section\">\n\t    \t<div class=\"container\" >\n\t    \t\t<h1 className=\"title is-size-4-mobile\" id=\"point\">IDENTIFY Overview</h1>\n\t    \t\t\t\t<hr></hr>\n\t      </div>\n\n\t\t\t\t<div class=\"container has-text-centered\" >\n\t\t\t\t<figure className=\"media-content is-size-4-mobile\">\n\t\t\t\t\t\t<img id=\"imgcentre2\" src={IdentifyLogo}></img>\n\t\t\t\t</figure>\n\t\t\t\t<span class=\"title\"> The Investigation and DEtection of urological Neoplasia in paTIents reFerred with suspected urinary tract cancer: A multicentre analYsis (IDENTIFY)</span>\n\t\t\t\t<hr></hr>\n\t\t\t\t<span class=\"title\"> IDENTIFY Risk Calculator External Validation Study</span>\n\t\t\t\t</div>\n\t\t</section>\n\n\n\t\t<section className=\"section\">\n    \t<div class=\"container\" >\n    \t\t<h1 className=\"title is-size-4-mobile\"> <strong>Background </strong></h1>\n    \t\t\t\t<hr></hr>\n    \t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\tData from the IDENTIFY study has provided a predictive model to predict the risk\n\t\t \t\tof urinary tract cancer (bladder, renal and upper tract urothelial cancer) in patients\n\t\t\t\treferred to secondary care with haematuria, and without a previous history of\n\t\t\t\turological malignancy.\n\t\t\t\t</h2>\n\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\tThe risk calculator from the predictive model can be found online\n\t\t\t\t<a href = \"https://www.bursturology.com/Studies/Identify/Admin/\"> here </a> and on Apple and Android\n\t\t\t\tdevices as an app called “IDENTIFY Risk Calculator”.\n\t\t\t\t</h2>\n        </div>\n        </section>\n\n\t\t\t\t<section className=\"section\">\n\t\t\t\t\t<div class=\"container\" >\n\t\t\t\t\t\t<h1 className=\"title is-size-4-mobile\"> <strong>Study Design </strong></h1>\n\t\t\t\t\t\t\t\t<hr></hr>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\tProspective multicentre international study to validate the IDENTIFY risk calculator\n\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t</div>\n\t\t\t\t\t\t</section>\n\n\t\t<section className=\"section\">\n\t\t\t<div class=\"container\" >\n\t\t\t\t<h1 className=\"title is-size-4-mobile\"> <strong> Patients </strong></h1>\n\t\t\t\t\t\t<hr></hr>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t<b> Inclusion Criteria: </b>\n\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t<strong>1. </strong>Any patient aged 16 and over, with haematuria (visible or nonvisible)\n\t\t\t\t\t\tundergoing cystoscopy and investigation for urinary tract cancer.\n\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t  <b>Exclusion Criteria: </b>\n\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t<strong>1. </strong>Patients with a previous or known diagnosis of primary upper or lower urinary\n\t\t\t\t\t\ttract cancers (renal, ureteric, bladder, prostate, urethral and penile cancers).\n\t\t\t\t\t\tThis includes patients with suspected recurrence of urothelial cancers.\n\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t<strong>2. </strong>Patients undergoing cystoscopy for reasons unrelated to ruling out urothelial\n\t\t\t\t\t\tcancer.\n\t\t\t\t\t\t</h2>\n\t\t\t</div>\n\t\t</section>\n\n\t\t\t\t<section className=\"section\">\n\t\t    \t<div class=\"container\" >\n\t\t    \t\t<h1 className=\"title is-size-4-mobile\"> <strong>Objectives </strong></h1>\n\t\t    \t\t\t\t<hr></hr>\n\t\t    \t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t<b>Primary Objective:</b>\n\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t<strong>1. </strong> External validation of the IDENTIFY risk calculator\n\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t<b>Secondary Objective:</b>\n\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t<strong>1. </strong>Prevalence of urothelial cancer in patients referred to secondary care with\n\t\t\t\t\t\thaematuria.\n\t\t\t\t\t\t</h2>\n\t\t        </div>\n\t\t        </section>\n\n\t\t\t<section className=\"section\">\n\t    \t<div class=\"container\" >\n\t    \t\t<h1 className=\"title is-size-4-mobile\"> <strong>Outcomes </strong></h1>\n\t    \t\t\t\t<hr></hr>\n\t    \t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<b>Primary Outcomes:</b>\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<strong>1. </strong> Area under the receiver operating characteristic curve (AUC) for the detection\n\t\t\t\t\tof urinary tract cancer\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<strong>2. </strong> Calibration coefficient and intercept\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<b>Secondary Outcomes:</b>\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<strong>1. </strong>Prevalence of individual patient characteristics/variables used in the risk\n \t\t\t\t\tcalculator.\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<strong>2. </strong>Prevalence of urinary tract cancers overall and individually (bladder, renal and\n\t\t\t\t\t\tupper tract urothelial cancer) in the validation cohort\n\t\t\t\t\t</h2>\n\t        </div>\n\t        </section>\n\n\t\t\t<section className=\"section\">\n\t    \t<div class=\"container\" >\n\t    \t\t<h1 className=\"title is-size-4-mobile\"> <strong>Methods </strong></h1>\n\t    \t\t\t\t<hr></hr>\n\t    \t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\tPatient data should be collected from secondary care centres that evaluate patients\n\t\t\t\t\twith suspected haematuria and have the ability for cystoscopy (flexible or rigid) to be\n\t\t\t\t\tcarried out and trans-urethral resection of bladder tumours to be performed.\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\tTrainees, speciality doctors, consultants, nurses or equivalent that perform, assist or\n\t\t\t\t\thave access to cystoscopy lists are ideally suited to take part as collaborators.\n\t\t\t\t\tParticipating collaborators are required to register their site with the permission of a\n\t\t\t\t\tlocal consultant urologist. Participating collaborators will complete a data collection\n\t\t\t\t\ttool of prospective patients referred to the centre for cystoscopy +/- imaging tests to\n\t\t\t\t\trule out urinary tract cancer. Collaborators should ideally collect data as they see\n\t\t\t\t\teach patient in the cystoscopy clinic but this can be done immediately after a clinic if\n\t\t\t\t\tall of the data required is collected in the patient notes. All data collected is data that\n\t\t\t\t\tis routinely collected as part of haematuria assessments. Patients with suspected\n\t\t\t\t\tcancer findings undergoing further investigations or surgery (e.g. TURBT) should be\n\t\t\t\t\tfollowed up and the histopathology for these investigations and procedures should\n\t\t\t\t\tbe collected. Patients found to have cancer should be followed up until pathology is\n\t\t\t\t\tavailable (if applicable). It is not anticipated that follow up for any specific patient will\n\t\t\t\t\texceed 3 months.\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\tData will be entered directly onto a Redcap database. Only anonymised data will be\n\t\t\t\t\tcollected. Caldicott principles will be followed.\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<b>Data to be Collected:</b>\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<strong>1. </strong> IDENTIFY risk calculator variables\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<strong>2. </strong>  Presence and type of cancer\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<strong>3. </strong> Histopathological grade and staging\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t<b>Quality control:</b>\n\t\t\t\t\t</h2>\n\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\tAll data will be checked prospectively to ensure good quality data entry and\n\t\t\t\t\tcomplete records. Sites will be contacted to fill in missing data for mandatory fields.\n\t\t\t\t\t</h2>\n\t        </div>\n\t        </section>\n\n\t\t\t\t\t<section className=\"section\">\n\t\t\t\t\t\t<div class=\"container\" >\n\t\t\t\t\t\t\t<h1 className=\"title is-size-4-mobile\"> <strong>Sample Size </strong></h1>\n\t\t\t\t\t\t\t\t\t<hr></hr>\n\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\tThe unadjusted prevalence of urinary tract cancer from the IDENTIFY study was\n\t\t\t\t\t\t\t20.7%. On the basis of requiring 20 events per variable, with 13 variables, we\n\t\t\t\t\t\t\twould require a sample size of approximately 1250 patients.\n\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\tWe would expect each collaborator to collect data from at least 15 patients and so\n\t\t\t\t\t\t\twould require approximately 100 collaborators.\n\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t</section>\n\n\t\t\t\t\t\t\t\t<section className=\"section\">\n\t\t\t\t\t\t    \t<div class=\"container\" >\n\t\t\t\t\t\t    \t\t<h1 className=\"title is-size-4-mobile\"> <strong> Timeline </strong></h1>\n\t\t\t\t\t\t    \t\t\t\t<hr></hr>\n\t\t\t\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\t\t\t\t<strong>- </strong>January 2022 - March 2022: Registration\n\t\t\t\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\t\t\t\t<strong>- </strong>February 2022 - May 2022: Collect Data\n\t\t\t\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\t\t\t\t<strong>- </strong>May 2022 - June 2022: Data analysis\n\t\t\t\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\t\t\t\t<strong>- </strong>July 2022: Submission to journal\n\t\t\t\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t        </div>\n\t\t\t\t\t\t        </section>\n\n\t\t\t\t\t\t\t\t\t\t<section className=\"section\">\n\t\t\t\t\t\t\t\t\t\t\t<div class=\"container\" >\n\t\t\t\t\t\t\t\t\t\t\t\t<h1 className=\"title is-size-4-mobile\"> <strong> To qualify for collaborative authorship:</strong></h1>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<hr></hr>\n\t\t\t\t\t\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\t\t\t\t\t\t<strong>1. </strong>We would expect each collaborator to collect data from at least 15 patients and so\n\t\t\t\t\t\t\t\t\t\t\t\twould require approximately 100 collaborators.\n\t\t\t\t\t\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\t\t\t\t\t\tIt is intended that all people collecting data that meet the minimum site requirements,\n\t\t\t\t\t\t\t\t\t\t\t\tas specified in advance, would be recognised as PubMed Indexed collaborators. It is\n\t\t\t\t\t\t\t\t\t\t\t\tacknowledged that the specific format and display of this recognition is subject to\n\t\t\t\t\t\t\t\t\t\t\t\tspecific requirements of the journal that we submit to. We will acknowledge all\n\t\t\t\t\t\t\t\t\t\t\t\tcollaborators as part of the “IDENTIFY study group” on papers and in presentations\n\t\t\t\t\t\t\t\t\t\t\t\tof work. Evidence of contribution to the work will also be provided on the BURST\n\t\t\t\t\t\t\t\t\t\t\t\twebsite\n\t\t\t\t\t\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\t\t\t\t\t\tPeople who are the top recruiters to the study will be invited to the writing group,\n\t\t\t\t\t\t\t\t\t\t\t\tmain authorship line, and will be given preference for national and international\n\t\t\t\t\t\t\t\t\t\t\t\tscientific presentations of the work as well as for further work relating to this project.\n\t\t\t\t\t\t\t\t\t\t\t\tSpecialist advisors and peer reviewers will be specifically acknowledged for their\n\t\t\t\t\t\t\t\t\t\t\t\trole.\n\t\t\t\t\t\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t\t\t\t\t\t</section>\n\n\t\t\t\t\t<section className=\"section\">\n\t\t\t\t\t\t<div class=\"container\" >\n\t\t\t\t\t\t\t<h1 className=\"title is-size-4-mobile\"> <strong> Ethics and local governance:</strong></h1>\n\t\t\t\t\t\t\t\t\t<hr></hr>\n\t\t\t\t\t\t\t<h2 className=\"subtitle is-size-5-mobile\">\n\t\t\t\t\t\t\tThis project qualifies as a service evaluation as per HRA UK guidelines, and the data\n\t\t\t\t\t\t\tto be collected is non-identifiable. This will mean it is exempt from ethical approval.Each participating site will get audit department / R&D ethics exemption in writing\n\t\t\t\t\t\t\tand will send registration numbers, where applicable, to the IDENTIFY team. For\n\t\t\t\t\t\t\tinternational sites, local governance policies will be followed.\n\t\t\t\t\t\t\t</h2>\n\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t</section>\n\n\t\t<Footer />\n\t\t</html>\n);\n\nexport default IdentifyOverviewPage;\n","module.exports = __webpack_public_path__ + \"static/identify-684a176defdd1b4d81711871a5dd8032.jpeg\";"],"sourceRoot":""}